Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Men With Prostate Cancer Should Exercise

March 2nd 2011

Men with prostate cancer reduce the risk of death from all causes by 46% if they do moderate exercise, such as walking, for 90 minutes a week

Immunotherapy

August 16th 2010

Novel immunotherapy approaches to metastatic prostate cancer: Stimulating the immune response ex vivo with autologous antigen presenting cells.

BIO-BUZZ: QUADRAMETï¿½: A New Option for Hormone-Refractory Prostate Cancer?

August 16th 2010

The treatment of hormone-refractory prostate cancer often represents a therapeutic challenge. As the most common malignancy in men and the second-leading cause of cancer death in the US, the number of patients requiring posthormonal therapy is increasing.

The Rapid Reporter: April 2007

August 13th 2010

This month we report on presentations made at the BIO (Biotechnology Industry Organization)CEO & Investor Conference (February 11-14, 2007, New York, NY).

AUA Updates Prostate Cancer Guidelines

July 12th 2010

The first revision in 12 years, the new guidelines are based on a growing body of evidence-based research and emphasize communication with the patient regarding risk, treatment options, and potential outcomes.

Patient Recruitment Completed for First Phase III Clinical Trial of GVAX Immunotherapy for Prostate Cancer

July 8th 2010

Cell Genesys has announced that it has completed recruitment of more than 600 patients into VITAL-1, the first of two ongoing Phase III clinical trials of GVAX immunotherapy for prostate cancer.

Provenge Takes Personalized Care to a New Level

June 12th 2010

Provenge becomes the first immunotherapy vaccine against cancer to win FDA approval

Judge Rules Myriad Cannot Patent BRCA1 and BRCA2-Genes

April 4th 2010

A US district court invalidated 7 of 23 of Myriad Genetics, Inc's patents on the BRCA1 and BRCA2 genes, which confer an increased risk of developing breast, ovarian, and prostate cancers.

GPS for the Body: Treating a Moving Target

February 25th 2009

A common treatment option for prostate cancer is radiation therapy, which is as effective in treating the disease as surgical removal of the prostate.